MethylGene logo

MethylGene

Harnessing Innovation to Develop Next-Generation Cancer Therapies

est. 1997

VS
Shield Therapeutics plc logo

Shield Therapeutics plc

Helping patients become people again

71 employees · est. 2008 · United Kingdom

MethylGene is the older company (1997 vs 2008).

Side-by-Side Comparison

MethylGene Shield Therapeutics plc
Founded
1997 older 2008
Headquarters
Not tracked yet United Kingdom
Employees
Not tracked yet 71
Industry
Biopharma, Biotechnology Biotechnology, Health and Wellness, Pharmaceutical
Funding Stage
Series Unknown Post Ipo Debt
Total Funding
$71.83M $33.20M
Funding Rounds
4 3
Services
Not tracked yet Not tracked yet
Target Customers
Not tracked yet Not tracked yet
Taxonomy
Biopharmaceutical Company, Clinical Stage, Cancer Therapeutics, Kinase Inhibitors, HDAC Inhibitors, Oncology, Pharmaceutical Research, Clinical Trials, Drug Development, Neurodegenerative Diseases, Publicly Traded, Oncology Treatments, MethylGene Inc., Taiho Pharmaceutical Co. Ltd. Specialty Pharmaceuticals, Iron Deficiency, Accrufer, Feraccru, Global Pivotal Phase III Studies, Inflammatory Bowel Disease, Chronic Kidney Disease, Switzerland, Independent Pharmaceutical Company, Global Commercialization, Mineral-derived Hospital Pharmaceuticals, Norgine B.V., Beijing Aosaikang Pharmaceutical Co., Ltd., Korea Pharma Co., Ltd., KY Pharmaceuticals Inc.
Website
methylgene.com shieldtherapeutics.com
MethylGene logo

About MethylGene

MethylGene is a clinical stage biopharmaceutical company dedicated to the development and commercialization of innovative therapeutics primarily targeting cancer. Founded in 1997, it trades on the public market under the symbol TSX:MYG. The company's product portfolio includes MGCD265, an oral, mult...

Shield Therapeutics plc logo

About Shield Therapeutics plc

Shield Therapeutics plc is a UK-based specialty pharmaceutical company that focuses on addressing iron deficiency through its lead product, Accrufer®/Feraccru® (ferric maltol). The company has already launched Accrufer® in the US, while Feraccru® is commercialized in the UK and European Union by Nor...

We will tell you when either one moves

BounceWatch watches MethylGene and Shield Therapeutics plc for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at MethylGene and Shield Therapeutics pl... — by email.

Frequently Asked Questions

MethylGene — Harnessing Innovation to Develop Next-Generation Cancer Therapies. Shield Therapeutics plc — Helping patients become people again. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
MethylGene has raised $71.83M while Shield Therapeutics plc has raised $33.20M.
MethylGene and Shield Therapeutics plc operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare MethylGene with someone else

Start typing a company name or domain.

Related Comparisons

Compiled from the BounceWatch company index. We last looked at MethylGene on 19 Jun 2024, and Shield Therapeutics plc on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy